Birdshot Chorioretinitis in Patients Aged 80 and Older.
Birdshot chorioretinitis
choroid
immunosuppressive therapy
long-term
posterior uveitis
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
19 May 2023
19 May 2023
Historique:
medline:
19
5
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
aheadofprint
Résumé
To assess the manifestations of birdshot chorioretinitis (BSCR) in patients aged 80 and over. Among patients with BSCR followed in the CO-BIRD prospective cohort (ClinicalTrials.gov Identifier: NCT05153057), we analyzed the subgroup of patients aged 80 and over. Patients were assessed in a standardized manner. Confluent atrophy was defined as hypoautofluorescent spots on fundus autofluorescence (FAF). We included 39 (8.8%) of the 442 enrolled CO-BIRD patients. The mean age was 83.8 ± 3.7 years. The mean logMAR BCVA was 0.52 ± 0.76, with 30 patients (76.9%) having 20/40 or better in at least one eye. Thirty-five (89.7%) patients were receiving no treatment. Confluent atrophy in the posterior pole, disrupted retrofoveal ellipsoid zone and choroidal neovascularization were associated with logMAR BCVA >0.3 ( In patients aged 80 and over we observed a striking heterogeneity of outcomes, but most retained a BCVA that allowed them to drive.
Identifiants
pubmed: 37204866
doi: 10.1080/09273948.2023.2215322
doi:
Banques de données
ClinicalTrials.gov
['NCT05153057']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM